These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34655838)

  • 1. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
    Maluf FC; Schutz FA; Cronemberger EH; Luz MA; Martins SPS; Muniz DQB; Bastos DA; Cárcano FM; Smaletz O; Soares A; Peixoto FA; Gomes AJ; Cruz FM; Franke FA; Herchenhorn D; Dos Santos TM; Fabricio VC; Gidekel R; Werutsky G; de Jesus RG; Souza VC; Fay AP
    Eur J Cancer; 2021 Oct; 158():63-71. PubMed ID: 34655838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels.
    Werutsky G; Maluf FC; Cronemberger EH; Carrera Souza V; Dos Santos Martins SP; Peixoto F; Smaletz O; Schutz F; Herchenhorn D; Santos T; Mavignier Carcano F; Queiroz Muniz D; Nunes Filho PRS; Zaffaroni F; Barrios C; Fay A
    BMC Cancer; 2019 May; 19(1):487. PubMed ID: 31122212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    Aggarwal R; Heller G; Hillman DW; Xiao H; Picus J; Taplin ME; Dorff T; Appleman L; Weckstein D; Patnaik A; Bryce A; Shevrin D; Mohler J; Anderson D; Rao A; Tagawa S; Tan A; Halabi S; Dooley K; O'Brien P; Chen R; Ryan CJ; Eggener SE; Morris MJ;
    J Clin Oncol; 2024 Apr; 42(10):1114-1123. PubMed ID: 38261983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
    Autio KA; Antonarakis ES; Mayer TM; Shevrin DH; Stein MN; Vaishampayan UN; Morris MJ; Slovin SF; Heath EI; Tagawa ST; Rathkopf DE; Milowsky MI; Harrison MR; Beer TM; Balar AV; Armstrong AJ; George DJ; Paller CJ; Apollo A; Danila DC; Graff JN; Nordquist L; Dayan Cohn ES; Tse K; Schreiber NA; Heller G; Scher HI
    Eur Urol Open Sci; 2021 Dec; 34():70-78. PubMed ID: 34934969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
    Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
    Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K
    Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
    Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
    Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
    Saad F; Efstathiou E; Attard G; Flaig TW; Franke F; Goodman OB; Oudard S; Steuber T; Suzuki H; Wu D; Yeruva K; De Porre P; Brookman-May S; Li S; Li J; Thomas S; Bevans KB; Mundle SD; McCarthy SA; Rathkopf DE;
    Lancet Oncol; 2021 Nov; 22(11):1541-1559. PubMed ID: 34600602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
    Fizazi K; Tran N; Fein L; Matsubara N; Rodriguez-Antolin A; Alekseev BY; Özgüroğlu M; Ye D; Feyerabend S; Protheroe A; Sulur G; Luna Y; Li S; Mundle S; Chi KN
    Lancet Oncol; 2019 May; 20(5):686-700. PubMed ID: 30987939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer.
    Aggarwal R; Alumkal JJ; Szmulewitz RZ; Higano CS; Bryce AH; Lopez-Gitlitz A; McCarthy SA; Miladinovic B; McQuarrie K; Thomas S; Zhang K; Small EJ
    Prostate Cancer; 2022; 2022():5454727. PubMed ID: 36212187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wang L; Paller CJ; Hong H; De Felice A; Alexander GC; Brawley O
    JAMA Oncol; 2021 Mar; 7(3):412-420. PubMed ID: 33443584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
    Chowdhury S; Bjartell A; Agarwal N; Chung BH; Given RW; Pereira de Santana Gomes AJ; Merseburger AS; Özgüroğlu M; Soto ÁJ; Uemura H; Ye DW; Brookman-May SD; Londhe A; Bhaumik A; Mundle SD; Larsen JS; McCarthy SA; Chi KN
    Future Oncol; 2024 Mar; 20(10):563-578. PubMed ID: 38126311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies.
    Karsh LI; Bevans KB; Saad F; Chung BH; Oudard S; Brookman-May SD; McCarthy SA; Smith MR; Chi KN; Small EJ; Agarwal N
    Future Oncol; 2024; 20(35):2689-2698. PubMed ID: 39163505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
    Sydes MR; Spears MR; Mason MD; Clarke NW; Dearnaley DP; de Bono JS; Attard G; Chowdhury S; Cross W; Gillessen S; Malik ZI; Jones R; Parker CC; Ritchie AWS; Russell JM; Millman R; Matheson D; Amos C; Gilson C; Birtle A; Brock S; Capaldi L; Chakraborti P; Choudhury A; Evans L; Ford D; Gale J; Gibbs S; Gilbert DC; Hughes R; McLaren D; Lester JF; Nikapota A; O'Sullivan J; Parikh O; Peedell C; Protheroe A; Rudman SM; Shaffer R; Sheehan D; Simms M; Srihari N; Strebel R; Sundar S; Tolan S; Tsang D; Varughese M; Wagstaff J; Parmar MKB; James ND;
    Ann Oncol; 2018 May; 29(5):1235-1248. PubMed ID: 29529169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study.
    Posadas EM; Chi KN; de Wit R; de Jonge MJA; Attard G; Friedlander TW; Yu MK; Hellemans P; Chien C; Abrams C; Jiao JJ; Saad F
    Clin Cancer Res; 2020 Jul; 26(14):3517-3524. PubMed ID: 32366670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.